

GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS

PROSTAGLANDIN ANALOGUES AND COMBINATIONS

HPGST SSB – Ref# 612-D: Lumigan, Rocklatan, Xelpros, Vyzulta

TGST SSB – Ref# 613-D: Lumigan, Rocklatan, Xelpros, Vyzulta

Status: CVS Caremark Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of at least one generic prostaglandin analogue drug within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested branded prostaglandin analogue drug will be covered with post step therapy prior authorization when the following criteria are met:

- The patient has experienced an inadequate treatment response after at least a 30 day trial of at least one generic prostaglandin analogue drug
OR
- The patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic prostaglandin analogue drug
OR
- The patient has experienced an intolerance to at least one generic prostaglandin analogue drug

RATIONALE

If the patient has filled a prescription for at least a 30 day supply of at least one generic prostaglandin analogue drug within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried at least one of the generic drugs for at least 30 days and had an inadequate treatment response, then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

REFERENCES

N/A

Written by: UM Development (NB)
Date Written: 01/2011

GSTP Prostaglandin Analogues & Combos 612-D, 613-D 11-2022 v2

© 2023 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.

Revised: 05/2011, 02/2012, 04/2012 (added Zioptan), 09/2012 (updated formatting and documentation), 10/2012 (removed documentation), 02/2013, 11/2013 (reworded question #2), 11/2014, 11/2015, 11/2016 (no changes), (SF) 11/2017 (no changes), 10/2018 (no changes), 01/2019 (removed Travatan Z), 07/2019 (added Rocklatan, Xelpros, Vyzulta), 10/2019 (updated with template language), 10/2020 (no changes), (DFW) 10/2021 (no clinical changes), 10/2022 (no clinical changes), 12/2022 (removed Zioptan)

Reviewed: Medical Affairs 01/2011, (KP) 02/2012, 04/2012; (DC) 09/2012, (LS) 02/2013, (LS) 11/2013, (DC) 11/2014, (EPA) 07/2019, (CHART) 10/31/2019, (CHART) 10/29/2020, (CHART) 10/28/2021, 10/27/2022, 01/12/2023

External Review: 04/2011, 04/2012, 04/2013, 02/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019, 08/2019, 02/2020, 12/2020, 12/2021, 12/2022, 02/2023 (FYI)

CRITERIA FOR APPROVAL

- | | | | |
|---|--|-----|----|
| 1 | Has the patient experienced an inadequate treatment response after at least a 30 day trial of at least one generic prostaglandin analogue drug?
[If yes, then no further questions.] | Yes | No |
| 2 | Does the patient have a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic prostaglandin analogue drug?
[If yes, then no further questions.] | Yes | No |
| 3 | Has the patient experienced an intolerance to at least one generic prostaglandin analogue drug? | Yes | No |

Mapping Instructions

	Yes	No
1	Approve, 24 months	Go to 2
2	Approve, 24 months	Go to 3
3	Approve, 24 months	Deny

GSTP Prostaglandin Analogues & Combos 612-D, 613-D 11-2022 v2

© 2023 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.